Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Saulius K. Girnius, Joshua Richter, Kimberly Bogard, Habte A. Yimer, Sudhir Manda, Roger M. Lyons, Stephen J. Noga, Robert M. Rifkin

Blood (2023) 142 (Supplement 1): 6677.

https://doi.org/10.1182/blood-2023-179795

Published: 2023

Journal Articles

Real-World Clinical Outcomes Among Triple-Class Exposed Multiple Myeloma Patients and Subgroups in the US Oncology Network

Robert M. Rifkin, Jennifer S. Harper, Hoa H. Le, Alex Z. Fu, Saurabh N. Patel, Xinke Zhang, Ira L. Zackon

Blood (2023) 142 (Supplement 1): 7362.

https://doi.org/10.1182/blood-2023-186616

Published: 2023

Journal Articles

Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

Robert M. Rifkin, Jeff P. Sharman, Jessica Fowler, Thomas S. Lin, Brian Thomson, Jesus G. Berdeja

Blood (2023) 142 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2023-185257

Published: 2023

Journal Articles

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Hans C. Lee, Rafat Abonour, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Mohit Narang, James Omel, Robert M. Rifkin, Howard Terebelo, Kathleen Toomey, Lynne I. Wagner, Samantha Slaff, Dailan Danforth, Weiyuan Chung, Jasmeet Anand, Edward Yu, Derek Tang, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 13256–13258.

https://doi.org/10.1182/blood-2022-158197

Published: 2022

Journal Articles

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Joshua Richter, Sikander Ailawadhi, Hans C. Lee, James W. Hardin, Howard R. Terebelo, Rafat Abonour, Lynne I. Wagner, Brian G.M. Durie, James L. Omel, Mohit Narang, Kathleen Toomey, Robert M. Rifkin, Cristina J. Gasparetto, Edward Yu, Jasmeet Anand, Liang Liu, Ying-Ming Jou, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 8089–8091.

https://doi.org/10.1182/blood-2022-158627

Published: 2022

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Ruemu E. Birhiray, Robert M. Rifkin, Christopher A. Yasenchak, January Fields-Meehan, Roger M. Lyons, Ramalingham Ratnasabapathy, Kimberly Bogard, Kim Tran, Dasha Cherepanov, Stephen J. Noga, Saulius K. Girnius, Stephen J. Noga

Blood (2022) 140 (Supplement 1): 7322–7323.

https://doi.org/10.1182/blood-2022-163071

Published: 2022

Journal Articles

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Robert M. Rifkin, Stephen J. Noga, Saulius K. Girnius, Kimberly Bogard, Sudhir Manda, Habte Yimer, Presley Whidden, Ruemu E. Birhiray, Philip Twumasi-Ankrah, Yikun Guo, Rami Owera, Leon Bernal-Mizrachi, Roger Lyons

Blood (2021) 138 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2021-150094

Published: 2021

Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2757.

https://doi.org/10.1182/blood-2021-145903

Published: 2021

Journal Articles

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Blood (2021) 138 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2021-148481

Published: 2021

Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Blood (2021) 138 (Supplement 1): 2746.

https://doi.org/10.1182/blood-2021-152681

Published: 2021

Journal Articles

Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect ® Multiple Myeloma (MM) Disease Registry

Blood (2021) 138 (Supplement 1): 117.

https://doi.org/10.1182/blood-2021-146830

Published: 2021

Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2021) 137 (26): 3616–3628.

https://doi.org/10.1182/blood.2020008787

Published: 2021

Includes: Supplemental data

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K. Girnius, MD, Habte A. Yimer, MD, Stephen J. Noga, MDPhD, Sudhir Manda, MD, Roger M. Lyons, MD, Kimberly Bogard, PharmD, Presley Whidden, Dasha Cherepanov, Vickie Lu, PhD, Jack Aiello, EE, MS, BS, Joshua R. Richter, MD, Robert M. Rifkin, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140482

Published: 2020

Journal Articles

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

Lisa La, Sundar Jagannath, MD, Sikander Ailawadhi, Brian G.M. Durie, MD, Cristina J. Gasparetto, MD, James W. Hardin, PhD, Hans C. Lee, MD, Mohit Narang, MD, James L. Omel, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, Lynne I. Wagner, PhD, Mazaher Dhalla, PharmD, Liang Liu, MS, Ling Yang, MS, Prashant Joshi, MD, Rafat Abonour, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-137309

Published: 2020

Journal Articles

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-139181

Published: 2020

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Robert M. Rifkin, MD, Sudhir Manda, MD, Stephen J Noga, MD PhD, Habte A Yimer, MD, Saulius K. Girnius, MD, Ruemu Ejedafeta Birhiray, MD, Christopher A. Yasenchak, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 1882.

https://doi.org/10.1182/blood-2019-124747

Published: 2019

Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Blood (2019) 134 (Supplement_1): 1887.

https://doi.org/10.1182/blood-2019-125749

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

NARROW

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Real-World Clinical Outcomes Among Triple-Class Exposed Multiple Myeloma Patients and Subgroups in the US Oncology Network

Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect ® Multiple Myeloma (MM) Disease Registry

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only